Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310100 · ClinicalTrials.gov registry record · NA
TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study
A NA study of Paroxysmal Atrial Fibrillation, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 178
- Enrollment target
- 20
- Study locations
NCT02310100: Completed NA study of Paroxysmal Atrial Fibrillation, sponsored by Abbott Medical Devices.
NCT02310100 is a NA study of Paroxysmal Atrial Fibrillation that has completed, run by Abbott Medical Devices. The registered enrollment target is 178 participants, below the 852-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02310100, a NA study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 178 participants
- Enrollment target
- 20
- Study locations
Study Summary
A prospective, multicenter, interventional study to collect confirmatory evidence on the safety and effectiveness of the TactiCath® percutaneous ablation catheter in the post approval setting for the treatment of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated radiofrequency ablation.
Primary Outcome
Rate of subjects free from symptomatic Paroxysmal Atrial Fibrillation (PAF), Atrial Flutter (AFL), and Atrial Tachycardia (AT) lasting longer than 30 seconds through 9 months of follow-up after a 3 month blanking period compared to a stated performance goal. Procedural failure defined by any of the following events: (1) Documented recurrence of AF/AFL/AT during the 9-month observational period lasting longer than 30 seconds; (2) Repeat ablation following the blanking period; or (3) Use of s new
Conditions Studied
Interventions
- DEVICE TactiCath Quartz treatment
Study Locations (20)
California
- Glendale Memorial Hospital and Health Center - Glendale
- Regional Cardiology Associates - Sacramento
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Womens Hospital - Boston
Michigan
- Cardiology Consultants of East Michigan - Flint
- Providence Hospital - Southfield
New York
- Mount Sinai Hospital - New York
- Stony Brook University Medical Center - Stony Brook
Texas
- Texas Cardiac Arrhythmia - Austin
- The Methodist Hospital - Houston
Georgia
- Emory University Hospital - Atlanta
Kansas
- Kansas University Medical Center - Kansas City
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2021-09-17 |
| Phase | NA |
What the finished NCT02310100 record still lists
NCT02310100 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, below the 852-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which TactiCath Quartz treatment is the first listed.
NCT02310100 names 20 study sites across 15 states, led by California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT02310100 about?
NCT02310100 is a clinical study titled "TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study". A prospective, multicenter, interventional study to collect confirmatory evidence on the safety and effectiveness of the TactiCath® percutaneous ablation catheter in the post approval setting for the treatment of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated radio...
What is the current status of trial NCT02310100?
This trial is currently completed. It is a NA study. The enrollment target is 178 participants. The study started on 2015-01-21. Estimated completion is 2021-09-17.
What conditions does trial NCT02310100 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT02310100?
The interventions under investigation include: TactiCath Quartz treatment (DEVICE).
Who is sponsoring clinical trial NCT02310100?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02310100 being conducted?
This trial has 20 study locations across California, Georgia, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02310100's enrollment target sits among peer trials
178 16th of 24 higher than 9 of 24 other Paroxysmal Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
-
POLARx Post Approval Study (POLARx PAS)
RECRUITING · NA
-
Treatment of PAF With the Synaptic System
ACTIVE NOT RECRUITING · NA
-
Meditation and Education That is Nurse Delivered for Symptom Management in Paroxysmal Atrial Fibrillation (PAF)
ACTIVE NOT RECRUITING · NA
-
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642002 · 178 participants · NA
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
- NCT04227847 · 178 participants · Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- NCT04855214 · 178 participants
Evaluating the Experience of Upper Limb Prosthesis Use
- NCT05391126 · 178 participants · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI